⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NBIX News
Neurocrine Biosciences Inc
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
prnewswire.com
NBIX
Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale
prnewswire.com
NBIX
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
prnewswire.com
NBIX
Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR
prnewswire.com
NBIX
Form 8-K
sec.gov
NBIX
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
prnewswire.com
SLNO
NBIX
Centri Announces Panel Topics and Featured Programming for Second Annual Capital Conference at Nasdaq on April 14
accessnewswire.com
NDAQ
DFIN
PTGX
STRL
TNDM
AXSM
CSTL
CYTK
GILD
INSM
KODK
NBIX
OCGN
REGN
SRPT
VRTX
XBIT
AMZN
GOOGL
MSFT
NVDA
IBM
ORGN
BWEN
CCJ
EXC
NEE
SO
UTL
XOM
BALY
OXY
PBF
CHRD
AX
BAC
MAXN
PHIO
KZR
SMX
DUOT
COIN
EHTH
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings
prnewswire.com
NBIX
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer
prnewswire.com
NBIX
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum
prnewswire.com
NBIX